zurück zur Startseite
Zentrale Tel.: 06221-560

Patient studies with Broccoli sprouts

Capsules containing broccoli sprout grain. In the Heidelberger Powder study patients receive 15 capsules (90mg sulforaphane) daily concomitant to chemotherapy

 

Other researchers in malignant tumors of the breast and prostate confirmed now our laboratory data. Our laboratory tests are supported by epidemiological studies in which dietary habits of large populations respective to the risk of cancer or the progression of a cancer were evaluated.

In a nutritional study for patients with prostate cancer, the researchers found that the frequent consumption of broccoli or cauliflower (3 to 5 servings a week), reduced the scattering of the tumor in some patients by 50%. A cancer preventive effect of cruciferous vegetables has been widely demonstrated in other studies. Numerous studies show that sulforaphane and his relatives help against inflammation, bacterial infections and viruses and inhibit tumor growth. Likewise recent data point to a positive effect on the intestinal flora by broccoli and cauliflower. This is of great importance, as a healthy intestinal flora is the basis for a healthy immune system and strong body’s defense against tumor cells.

 

 

Recurrent Prostate Cancer: At OHSU Knight Cancer Institute in Portland (Oregon, USA), a pilot study was conducted to investigate the effect of sulforaphane from broccoli sprouts extract in 20 patients with a recurrent prostate cancer (ClinicalTrials.gov Identifier: NCT01228084). For 20 weeks daily, sulforaphane was administered in doses of 200 μmol (88 mg), in four capsules of 50 μmol. This study has been completed and the preliminary studies show:

 

  • in 25% of patients the PSA level dropped more then 50% without the patient showing any serious side effects.
  • in 90% of patients the PSA level did not double.
  • there have been no serious side effects (grade 3 toxicity).
  • Half-life of sulforaphane in the blood: 2 to 5,5 hours

Although it is only a pilot study, this data raise hope and must be confirmed now with a larger number of patients. Detailed study results are not yet published, Opens external link in new windowpreliminary data can be found here:

 

Skin cancer prevention:  A now ongoing pilot study, which is conducted at the University of Pittsburgh (USA), examines the effectiveness of broccoli sprouts in atypical nevi, which are precursor lesions of malignant melanoma (ClinicalTrials.gov Identifier NCT01568996). Eighteen individuals receive a capsule with sulforaphane from broccoli sprout extract in the concentrations of 50 μmol (22 mg), 100 μmol (44 mg) or 200 μmol (88 mg) for 28 days orally. Study results are not available yet, the current status can be found here.

 

Bladder cancer: In another at the moment conducted pilot study at the Rosswell Park Cancer Institute in New York (USA), the effect of sulforaphane from broccoli sprouts extract is examined on the growth of urothelia carcinoma of the bladder. (NLM Identifier: NCT01108003). After the resection of the carcinoma the patients receive 200 μmol (88 mg) sulforaphane for 14 days daily. Study results are not available  yet, Opens external link in new windowthe current status can be found here. 

 

 

Pancreatic cancer: A study with broccoli sprouts packed in capsules as an adjuvant therapy of advanced pancreatic cancer started in December 2013 at the Surgical University Clinic Heidelberg (ClinicalTrials.gov identifier: NCT01879878). Forty patients with advanced pancreatic cancer who are undergoing surgery in Heidelberg are included. Half of the patients receive a chemotherapy AND broccoli sprouts with 90 mg sulforaphane daily, the other half gets only chemotherapy. The effect of the quality of life, tumor marker, tumor growth and survival is evaluated. The performance of this pilot study was supported by the Foundation of Surgery and a donation by Mr. Deiters (Deiters & Florin).

Interim report 9.4.2018:

Unfortunately, results of the broccoli patient study are not available yet - there was just an interim result, which has shown that too much data is missing to make credible statements. The problem was that there were too many external patients who we couldn't follow up from Heidelberg and who did not report back as agreed. Another big problem was that the supervising study doctor changed the clinic and therfore the leader was missing. The few existing data from tumor markers speak so far for the broccoli sprouts, albeit beyond a statistical significance. It is encouraging that there were no serious side effects, except partially disgust from the cabbage flavor, which is of course particularly bad in existing digestive disorder. Many patients were also bothered that they did not know if they were in the placebo or drug group. because broccoli sprouts are freely available, some patients have discontinued the study and taken broccoli sprouts on their own. In order to complete the study, funds for a study nurse and the procurement of broccoli sprouts must first be raised again. So far there is no sponsor.

 

 

 

 

 


Initiates file downloadAdditional Information can be found here.

 

Select languageSelect languageSelect language
Print Diese Seite per E-Mail weiterempfehlen